Topical antibiotic combination

11 marketed 5 in Phase 3

This page covers all Topical antibiotic combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide), Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane and proteins (chlorhexidine), Bacterial 50S ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide).

Targets

Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide) · Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane and proteins (chlorhexidine) · Bacterial 50S ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide) · Propionibacterium acnes (bacterial target); benzoyl peroxide acts via oxidative mechanism; clindamycin inhibits bacterial protein synthesis · Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane (chlorhexidine) · Bacterial cell wall (bacitracin), bacterial ribosome (neomycin), bacterial cell membrane (polymyxin B) · Bacterial ribosomes (clindamycin); reactive oxygen species generation (benzoyl peroxide) · Bacterial ribosome (clindamycin); oxidative stress induction (benzoyl peroxide) · Bacterial cell wall (bacitracin) and bacterial cell membrane (polymyxin B) · Bacterial ribosome (clindamycin); oxidative mechanism (benzoyl peroxide)

Marketed (11)

Phase 3 pipeline (5)